Mark Gordon

Mark Gordon practices at Xeron Clinical Laboratories Inc. in Long Island City, New York.

Mark Gordon's NPI, 1497183404, was assigned on October 30, 2013. Mark Gordon holds Florida license 11017993.

Mark Gordon's primary practice is Xeron Clinical Laboratories Inc., at 48-25 36th St, Long Island City, NY 11101 in Queens County. The practice phone is (212) 734-6621.

Mark Gordon's primary practice is Xeron Clinical Laboratories Inc. in Long Island City, New York. The medical group on file is Prestige Clinicians. Dmand AI also links Mark Gordon to 2 more group practices and clinics, 2 medical groups and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Gordon practices, 3 sites in all. Vendor and product names are available with a free account.

Family is Mark Gordon's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Mark Gordon is licensed in Florida.

CMS counts 125 Medicare patients who saw Mark Gordon in 2024. The largest group is under 65, with 45 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 67% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mark Gordon's median patient age at 51, with 48% women.

In 2024, Mark Gordon wrote 1,670 Medicare Part D claims for 181 patients. 89% of them were for generic drugs.

Mark Gordon accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 3 general payments to Mark Gordon from 2 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $120.